Redcare Pharmacy Achieves Significant Growth in 2024

Redcare Pharmacy N.V. reported a robust performance for 2024, with sales increasing by 32% to EUR 2.4 billion. Notably, the German Rx segment experienced an impressive 142% growth in Q4 compared to the previous year. The company attributed this growth to the adoption of e-prescriptions as a new standard in Germany.

Redcare's total revenue for Q4 amounted to EUR 674 million, marking a 27% increase year-over-year. The non-Rx sales in the quarter reached EUR 442 million, while Rx sales contributed EUR 232 million. Full-year Rx sales in Germany totaled EUR 254 million.

The DACH markets—Germany, Austria, and Switzerland—posted a 26.6% sales increase in Q4 to EUR 557 million. The International segment, covering Belgium, Italy, France, and the Netherlands, recorded a 28.5% rise in sales.

The company expanded its active customer base to 12.5 million by year-end, up by 1.7 million since 2023. Redcare executives lauded the company's successful digital initiatives and marketing campaigns.